Prescribing biosimilars by Aronson, Jeffrey K et al.
 
 
University of Birmingham
Prescribing biosimilars
Aronson, Jeffrey K; Goldacre, Ben; Ferner, Robin E
DOI:
10.1136/bmj.k3141
License:
Creative Commons: Attribution-NonCommercial (CC BY-NC)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Aronson, JK, Goldacre, B & Ferner, RE 2018, 'Prescribing biosimilars', BMJ, vol. 362, pp. k3141.
https://doi.org/10.1136/bmj.k3141
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked for eligibility: 13/03/2019
This article has been accepted for publication in BMJ, 2018 following peer review, and the Version of Record can be accessed online at
https://doi.org/10.1136/bmj.k3141.
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
  1
Prescribing	biosimilars:	when	reluctance	overcomes	evidence	
Jeffrey	K	Aronson1	2	
honorary	consultant	physician	and	clinical	pharmacologist	
Ben Goldacre1 
senior clinical research fellow 
Robin	E	Ferner2	3	
honorary	professor	of	clinical	pharmacology	
1Centre	for	Evidence	Based	Medicine,	Nuffield	Department	of	Primary	Care	Health	
Sciences,	Oxford	OX2	6GG,	UK	
2West	Midlands	Centre	for	Adverse	Drug	Reactions,	City	Hospital,	Birmingham,	UK	
3Institute	of	Clinical	Sciences,	University	of	Birmingham,	UK	
	
Correspondence	to:	J	K	Aronson,	jeffrey.aronson@phc.ox.ac.uk	
	
Generic	formulations	of	small	molecules	are	usually	as	effective	as	originators,	have	
similar	harms,	and	are	cheaper	to	prescribe.	The	same	should	be	true	of	biosimilars,	
which	are	generic	equivalents	of	originator	biological	medicines	(biologics).1	
	 Two	years	ago2	we	cited	an	article	in	the	Financial	Times,3 whose author claimed that 
the UK had been slow to adopt biosimilars. Here we provide evidence that that is so, based 
on the limited publicly available information on NHS prescribing of biosimilars. 
	 Biosimilars	are	biologics	that	are	highly	similar	to	other	already	approved	biologics	
and	are	themselves	approved	according	to	the	same	standards	of	pharmaceutical	
quality,	safety,	and	efficacy.4	They	are	not	necessarily	identical.	Consider,	for	example,	
monoclonal	antibodies.	Although	a	biosimilar	is	likely	to	preserve	the	primary	amino	
acid	sequence	of	the	originator,	differences	in	glycosylation,	deamination,	oxidation,	or	
three‐dimensional	structure	can	occur.	These	can	affect	interactions	with	target	
molecules,	which	could	lead	to	differences	in	benefits,	harms,	or	both,	between	
biosimilars	and	the	corresponding	originators.	This	may	be	the	case,	for	example,	with	
epoetins.5,6	
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	 Clinicians	face	two	problems:	choosing	between	an	originator	or	a	biosimilar	when	
starting	therapy	and	whether	to	switch	from	one	to	the	other	during	established	
therapy.	
	 There	are	principles	to	ensure	that	biosimilars	are	similar	enough,7	and	US	and	
European	regulators	demand	that	biosimilars	should	be	“highly	similar	to	the	reference	
medicinal	product	in	physicochemical	and	biological	terms”.8	This	includes,	for	example,	
pharmacokinetic	and	pharmacodynamic	similarity,	and	being	used	in	the	same	dosages	
as	the	originator	product.	Furthermore,	“any	observed	differences	have	to	be	duly	
justified	with	regard	to	their	potential	impact	on	safety	and	efficacy.”	The	principles	are	
included	in	guidance	from	the	US	Food	and	Drug	Administration,9	and	NICE	has	
provisions	for	recommending	biosimilars	when	appropriate.10	
	 There	is	some	reassuring	evidence	of	equivalence.	For	example,	two	infliximab	
biosimilars,	Remsima	and	Inflectra11,12,13	are	identical	to	the	originator,	Remicade,	in	
pharmaceutical	form,	strength,	composition,	and	route	of	administration.	The	biological	
actions	of	Remsima	are	essentially	identical	to	those	of	Remicade,	apart	from	minor	
pharmacodynamic	differences	that	appear	to	be	clinically	insignificant.14	The	
pharmacokinetics	are	almost	identical,	and	clinical	markers	of	disease	activity	respond	
equally	well	to	originator	and	biosimilar	products	in	rheumatoid	arthritis	and	
ankylosing	spondylitis.	
	 The	WHO	plans	to	prequalify	biosimilars	for	cancer	therapy,	giving	them	a	global	
stamp	of	approval.15	Comparability	of	quality,	safety,	and	efficacy	will	make	them	
eligible	for	procurement	by	UN	agencies.	This	should	increase	assurance	of	equivalence.	
	 However,	showing	that	two	products	are	of	equal	efficacy	does	not	prove	that	
switching	them	maintains	the	balance	of	benefits	and	harms	in	individual	patients.	For	
example,	in	an	18‐month	study	in	inflammatory	bowel	disease,	switching	from	
originator	infliximab	to	a	biosimilar	did	not	affect	efficacy,	but	13/143	patients	dropped	
out	because	of	adverse	events.16	
	 A	systematic	review	of	58	studies,	including	12	clinical	trials,	mostly	involving	
infliximab	or	epoetins,	suggested	that	the	expected	cost	savings	of	switching	
  3
outweighed	the	risks	of	anticipated	harms.17	A	later	review	of	57	studies,	covering	a	
wider	range	of	compounds	(infliximab	and	epoetins,	but	also	adalimumab,	etanercept,	
filgrastim,	follicle	stimulating	hormone,	genotropin,	insulin	glargine,	and	rituximab),	
reported	that	safety	and	efficacy	were	mostly	unchanged	after	switching.18	However,	
the	data	were	limited,	and	the	authors	commented	that	well	powered	and	appropriately	
analysed	clinical	trials	and	pharmacovigilance	studies,	with	long‐term	follow‐up	and	
multiple	switches,	were	needed.	
	 We	sought	evidence	about	UK	prescribing	of	biosimilars	in	two	publicly	accessible	
sources:	OpenPrescribing.net,	a	freely	available	website	containing	detailed	current	
data	on	all	prescribing	in	individual	English	general	practices19;	and	the	NHS	Medicines	
Optimisation	Dashboard,	which	contains	a	limited	number	of	prespecified	measures	at	
the	individual	NHS	Trust	level.20	Insulin	glargine	is	commonly	prescribed	in	primary	
care,	and	detailed	data	are	available	through	OpenPrescribing.net:	the	originator,	
Lantus,	still	accounts	for	90%	of	GP	prescriptions	(Figure	1);	the	biosimilar	Abasaglar	
accounts	for	around	60%	of	the	increased	number	of	prescriptions	since	it	was	licensed	
in	September	2015.	This	suggests	that	40%	of	new	patients	are	still	receiving	the	
originator,	whose	NHS	indicative	price	is	7%	higher,	and	that	switching	is	rare.	No	other	
biosimilars	are	commonly	prescribed	in	primary	care,	and	hospital	prescribing	data	are	
limited:	from	the	large	number	of	biosimilars	now	available	(Table	1),	the	Medicines	
Optimisation	Dashboard	gives	information	on	only	three	(Table	2).	Uptake	has	been	
incomplete.	This	may	have	substantial	cost	implications,	as	prices	are	high	and	
originators	typically	cost	about	10%	more	than	biosimilars.21	
	 Reasons	for	the	poor	uptake	of	biosimilars	may	include	lack	of	familiarity,	
therapeutic	inertia,	concern	about	patient	confusion	over	different	brand	names	and	
different	looking	formulations,	perceived	lack	of	efficacy,	the	nocebo	effect,22	and	
apparently	modest	percentage	price	differences.	
	 When	a	biosimilar	has	been	licensed,	there	should	be	no	concerns	about	starting	
treatment	with	it	rather	than	the	originator.	Switching	to	a	cheaper	product	in	a	patient	
who	is	already	taking	an	originator	can	also	be	recommended	when	there	is	high	quality	
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evidence	of	equivalence	of	the	benefits	and	harms,	provided	progress	is	then	carefully	
monitored.	
	
Table	1.	Examples	of	biosimilars	currently	approved	in	the	EU	and/or	USA	
	
Generic	
name*	
Originator	brand	
name	(company)	
Examples	of	biosimilar	brand	names	
(company)	
Adalimumaba	 Humira	(AbbVie)	 Imraldi	(Samsung	Bioepis/Merck)	
Darbepoetinb	 Aranesp	(Amgen)	 Retacrit	(epoetin	zeta;	Hospira)	
Silapo	(epoetin	zeta;	Stada	Arzneimittel)	
Epoetin	alfab	 Epogen/Eprex/Procrit	
(epoetin	alfa;	Amgen/	
Johnson	&	Johnson)	
Abseamed	(Medice	Arzneimittel	Pütter)	
Binocrit	(Sandoz)	
Etanerceptc	 Enbrel	
(Amgen/Pfizer)	
Brenzys/Benepali	(Samsung	Bioepis/Merck)	
Erelzi	(Sandoz)	
Filgrastimb	 Neupogen	(Amgen)	 Biograstim	(CT	Arzneimittel)	
Filgrastim	Hexal	(Hexal)		
Grastofil	(Apotex)	
Infliximaba	 Remicade	(Johnson	&	
Johnson/Merck)		
Flixabi/Renflexis	(Samsung	Bioepis/Merck)	
Remsima/Inflectra/Flammegis	
(Celltrion/Hospira)	
Insulin	
glargined	
Lantus	(Sanofi)	 Abasaglar/Basaglar	(Eli	Lilly/Boehringer	
Ingelheim)	
Semglee	(Mylan/Biocon)	
Rituximaba	 MabThera/Rituxan	
(Roche)	
Truxima/Blitzima/Ritemvia/Rituzena	
(Celltrion/Hospira)	
Teriparatided	 Forteo/Forsteo	(Eli	
Lilly)	
Movymia	(Stada	Arzneimittel)	
Terrosa	(Gedeon	Richter/Mochida	
Pharmaceutical)	
Trastuzumaba	 Herceptin	(Roche)	 Ontruzant	(Samsung	Bioepis/Merck)	
*Hyperlinks	are	to	entries	in	the	GaBi	(Generics	and	Biosimilars	Initiative)	website	(last	
accessed	15	June	2018)	
aMonoclonal	antibodies;	bGlycoproteins;	cFusion	protein;	dPolypeptide	hormones	
	
Table	2.	Current	percentage	uptakes	of	three	biosimilars	in	hospitals	
	
	
Drug	
Percentage	uptake	
Median	 Interquartile	range	
Etanercept	 76%	 60–90%	
Infliximab	 90%	 85–98%	
Rituximab	 60%	 42–76%	
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